Cadence
Automates chronic care for older adults using AI
$100MSeries C
Role not disclosedGC
General Catalyst
Activity from announced rounds
Activity in this selectionJun 30, 2026 · Jun 1, 2026
General Catalyst backs companies from formation and seed through growth, and also creates businesses with founders through its Creation strategy.
Creation includes starting companies in complex or emerging industries, helping experienced founders launch again and combining existing service businesses with applied AI. That makes GC relevant both to founders raising for an established startup and to entrepreneurs developing a new company with an investment partner.
For businesses that have reached product-market fit, its Customer Value Fund provides a separate way to finance customer acquisition. This sits alongside seed and growth equity, giving the firm a financing model directed specifically at the cost of expanding a customer base.
Sources
- Rounds participated in
- 8
- Confirmed lead rounds
- — 8 roles undisclosed
- New companies
- 8 First participation on record · 0 follow-on
- Funding in participating rounds
- $1.8B 8 disclosed · full round size, not this investor’s share
By stage
By primary sector
1 more
Industrial tech1
By country
Rounds
8 in this selectionStandard Bots
Manufactures AI-native industrial robots for automation
$200MSeries C
Role not disclosedCurrent
Provides consumer fintech platform helping everyday Americans improve their financial lives
$80MSeries E
Role not disclosedBeacon
Brings frontier technology to the real economy with AI-native business operating system
$225MSeries C
Role not disclosedPhysicsX
Builds AI-native engineering simulation software compressing months of design work into seconds for manufacturing and defence
$300MSeries C
Role not disclosedRamp
Provides financial infrastructure for corporate cards, invoicing, and expense management
$750MSeries F
Role not disclosedFactorial
AI-powered workforce operations platform helping businesses manage HR, finance, and IT through agentic workflows
$150MSeries D
Role not disclosedWaypoint Bio
Develops AI-designed CAR T therapies for solid tumors using spatial biology
$20MSeries A
Role not disclosed